AKCÝÐER KANSERLÝ OLGULARDA TEÞHÝS ANINDA AKCÝÐER TÜBERKÜLOZU BÝRLÝKTELÝÐÝ

Akciðer kanseri (AK)'ne eþlik eden hastalýklar içinde kardiyovasküler hastalýklar ve kronik obstrüktif akciðer hastalýðý ön planda olsa da nadiren akciðer tüberkülozu (TB) görülebilmektedir. Akciðer kanserli olgularda teþhis anýnda aktif akciðer TB birlikteliðini gözden geçirmek için Ocak 1999-Ocak 2005 tarihleri arasýnda AK teþhisi konulan 2152 olgunun bilgileri deðerlendirilmiþtir. Olgularýn 29 (%1.35)'inde geçirilmiþ (sekel) akciðer TB, 13 (%0.6)'sýnda aktif akciðer TB ve bir (%0.05)'inde aktif akciðer TB ile eþ zamanlý olarak TB plörezi saptanmýþ idi. Histopatolojik olarak en sýk (%46.1) skuamöz hücreli AK teþhis edildi. Akciðer TB, en sýk (%84.6) üst loblarda yerleþmiþ idi. Dört olguda kavite görülürken, olgularýn tümünde infiltratif lezyonlar saptandý. Sonuç olarak; akciðer kanserli olgularda, teþhis edildikleri dönemde nadir de olsa aktif akciðer tüberkülozu görülebildiði, bu olgularda akciðer kanserinin genellikle ileri evrelerde teþhis edildiði, tüberkülozun en sýk üst loblarý tuttuðu ve tüm olgularda infiltratif lezyonlarýn hakim olduðu tespit edilmiþtir. Akciðer kanserinin ilk teþhis konma dönemi, takip ve tedavisi sýrasýnda TB birlikteliði olasýlýðý unutulmamalý, aktif akciðer TB teþhisi için gecikilmemelidir.

THE CO-MORBIDITY OF PULMONARY TUBERCULOSIS AT THE TIME OF DIAGNOSIS OF PATIENTS WITH LUNG CANCER

In lung canc er (LC), frequently seen co-morbid diseases are cardio-vascular diseases and chronic obstructive pulmonary disease, pulmonary tuberculosis (TB) may be seen rarely. To look at the co-morbidity of active pulmonary TB at the time of diagnosis of LC patients, we evaluated the data of 2152 cases those had been diagnosed LC from January 1999 to January 2005. Patients had been diagnosed to have old lung TB lesions in 29 (1.35%), active pulmonary TB in 13 (0.6%) and TB pleurisy with active pulmonary TB in one (0.05%). In histopathology, frequent type of carcinoma was squamous cell LC (46.1%). Pulmonary TB was located mostly on upper lobes (84.6%). Where a cavity was detected in four, infiltrative lesions were in all cases. It is concluded that; active pulmonary TB may be rarely seen at the time of lung cancer diagnosis, the diagnosis generally is made of advanced disease, TB is localized at the upper lobes and in all patients, causes infiltrative lesions. At the time of diagnosis and along the follow-up and therapy of LC, the possibility of co-morbid TB disease has not to be forgotten and not to be late for the diagnosis of active pulmonary TB.